As a generic drugmaker, Teva Pharmaceutical Industries (NYSE: TEVA) has the trappings of a safe investment at first glance. Theoretically, demand for generic medications should be relatively consistent, and it's reasonable to believe that ongoing purchases of such drugs would make for a solid base of recurring revenue, which could increase over time. First, the company has a troublesome debt load of $21.6 billion that looms very large in comparison to its market cap of only $10.4 billion.